Atlas Trials

Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

Clinical trial NCT02304809 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02304809
Sponsor
UNICANCER
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Solid TumorsHematologic CancersMetastatic Cancers
Start date
2014-10-13
Primary completion
2019-05-07
Enrollment
216

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.